BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...cap Monday after reporting data from its Phase II study of KarXT xanomeline/trospium chloride, a muscarinic receptor...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side...
BioCentury | Jun 28, 2019
Financial News

June 28 Financial Quick Takes: Karuna rises after IPO; plus Chi-Med, BeiGene and more

...this year from a Phase II trial of Karuna's lead candidate KarXT xanomeline/trospium chloride, a muscarinic receptor...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...combination of indacaterol, a long-acting adrenergic receptor beta 2 agonist (LABA), glycopyrronium bromide, a long-acting muscarinic receptor...
BioCentury | May 31, 2019
Financial News

New IPO filings include Adaptive, Morphic

...Karuna expects data from a Phase II trial of lead program KarXT xanomeline/trospium chloride, a muscarinic receptor...
BioCentury | May 14, 2019
Distillery Techniques

A mouse model to screen therapies for Williams syndrome

...oligodendrocytes in the brain observed in patients with Williams syndrome. In the model, the generic muscarinic receptor...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...late 2019, Karuna expects data from a Phase II trial of KarXT xanomeline/trospium chloride, a muscarinic receptor...
BioCentury | Apr 5, 2019
Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

...with COPD, including chronic bronchitis and emphysema, is an inhalable long-acting, selective M2 and M3 muscarinic receptor...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...is Anavex Life Sciences Corp.’s oral Anavex2-73, an aminotetrahydrofuran derivative agonist of σ-1 receptor and muscarinic receptor...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

...By late 2019, the company expects data from a Phase II trial of KarXT, a muscarinic receptor...
Items per page:
1 - 10 of 425